Arpida, Inc. Publishes Top-Line Data of Phase II "Intravenous-To-Oral" Switch Trial With Oral Iclaprim
12/19/2008 10:19:53 AM
More...
|
Arpida, Inc. to Restructure and Focus on Key Projects; Announces Reduction in Workforce
12/1/2008 7:05:06 AM
More...
|
U.S. Panel Votes Against Arpida, Inc. Antibiotic
11/21/2008 7:25:39 AM
More...
|
Arpida, Inc. Falls as Iclaprim Fears Spark Cash Concerns
11/19/2008 6:30:00 AM
More...
|
Arpida, Inc. Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008
10/14/2008 11:56:31 AM
More...
|
Arpida, Inc.'s iclaprim MAA Accepted for Review by European Medicines Evaluation Agency
8/21/2008 8:02:23 AM
More...
|
Arpida, Inc. Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim
5/27/2008 9:27:48 AM
More...
|
Arpida, Inc. Announces New CEO
4/25/2008 7:57:37 AM
More...
|
Arpida, Inc. Provides Comprhensive Overview of Pivotal Phase III Trial Data
4/17/2008 8:23:48 AM
More...
|
Arpida, Inc. Provides Further Comments on the Pivotal Phase III Trials Extensive Data to be Presented at the Upcoming ECCMID Conference
4/11/2008 7:25:19 AM
More...
|
|